retatrutide new zealand Emerging Weight Loss Injectables Retatrutide (LY3437943) | GCGR/GIPR/GLP-1R Agonist

In my experience, most patients are not informed that GLP-1 medications require ongoing use to maintain results

Of note, this trial employed an individualized titration schedule on a variety of background regimens, which is likely more applicable to typical clinical practice

If the price is high relative to the benefit, NICE can restrict access to specific patient groups (for example, only those with very high BMI or particular comorbidities), or reject NHS use altogether

Let me break it all down

Your body burns more of its stored fat because of increased metabolism

Retatrutide does not have FDA approval as of mid-2025